• Ardelyx presented real-world results showing lower serum phosphate levels following XPHOZAH (tenapanor) initiation at ASN Kidney Week 2026.
• The analysis covered more than 1,400 adults on dialysis, with phosphate reductions observed over six months.
• Similar reductions occurred across evaluated groups, including patients taking XPHOZAH without phosphate binders or alongside a single binder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231601PRIMZONEFULLFEED9852360) on October 23, 2026, and is solely responsible for the information contained therein.